Arctic Bioscience AS has today released its Annual Report 2021, including the Board of Directors report and financial statements. The report and annual accounts were approved by the Board of Directors after close of business on 6 April 2022.
The report is attached to this stock exchange notice and available on the company website.
At 12:00 CEST today, the company will host a webcast to present the annual report and full year 2021 results, followed by a Q&A.
Arctic Bioscience AS FY 2021 webcast presentation:
Date: Thursday April 7, 2022
Time: 12.00 CEST
Format: Webcast and Q&A
Participants will be required to register to view the webcast and participate in the Q&A.
For more information, please contact
Christer L. Valderhaug
CEO Arctic Bioscience
Phone: +47 920 84 601
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing nutraceutical and pharmaceutical products based on unique bioactive marine compounds from herring roe.
The company is developing HRO350 – a novel investigational drug candidate based on herring roe. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.
Herring roe contains lipids that are essential in maintaining cell membranes and omega -3 fatty acids that contribute to the normal functioning of brain, heart, and vision. Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as well as finished goods under the ROMEGA® brand. The strategy is to switch sales from bulk to finished goods and focus markets are USA and China.
Arctic Bioscience is led by a team of highly competent people with experience in developing marine oils and experience from global pharmaceutical companies.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.